Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Liver Metastases From Colorectal Cancer
NCT06283134Phase 1Not yet recruiting
- Sponsor
- China Medical University
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Oncolytic Viruses
01
Overview
Phase 1, open-label, single-arm trial of BioTTT001 in colorectal cancer (CRC), sponsored by China Medical University. Primary endpoints: Incidence of adverse events and Maximum Tolerated Dose at 42 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
BioTTT001
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06283134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06283134.